Cancer is an unusual enemy, as it's made from your own cells. Yet cancer cells carry mutations, and mutated proteins can look foreign. The immune system does catch many tumours, and the biggest change in cancer treatment in decades has been learning how to help it.
How it sees a tumour
- Neoantigens. Mutated proteins, shown on MHC, look foreign to T cells. Tumours with many mutations, such as melanoma and lung cancers from smoking, tend to respond better to immunotherapy.
- Viral proteins. Cancers caused by viruses, such as HPV in cervical cancer, display viral pieces.
- Missing flags. A tumour that loses MHC to hide from T cells can be spotted by natural killers.
The three phases
Called immunoediting, it has three stages:
- Elimination. The immune system destroys early tumours. Nobody knows how often this happens, as it leaves no symptoms. People on long-term immune suppression have a much higher risk of cancer, especially those driven by viruses, which supports the idea.
- Equilibrium. Some tumour cells survive, held in check, potentially for years.
- Escape. Under constant pressure, the variants that grow are the ones the immune system can't see or can't touch. This is Darwinian selection, applied to the tumour.
Melanoma transplanted accidentally with a donor organ has been reported in cases where the donor had been apparently cured for years. This shows that the donor's immune system had kept cells under control all that time.
How tumours escape
| Trick | What it does |
|---|---|
| Lose MHC or antigen | T cells have nothing to recognise |
| Show PD-L1 | Triggers the PD-1 brake on T cells that arrive |
| Recruit calming cells | Regulatory T cells and repair-type macrophages fill the tumour |
| Build a hostile neighbourhood | Low oxygen, used-up nutrients, signals such as TGF-beta and adenosine |
| Keep T cells out | Dense tissue around the tumour physically blocks them |
Long-running stimulation in the tumour also leaves T cells exhausted.
Immunotherapy
| Treatment | How it works | Used for |
|---|---|---|
| Checkpoint inhibitors | Antibodies block PD-1, PD-L1, or CTLA-4, releasing the brakes | Melanoma, lung, kidney and many others |
| CAR-T cells | A patient's T cells are engineered with a synthetic receptor, then returned | B cell leukaemias, lymphomas, myeloma |
| Bispecific antibodies | One arm grips a T cell and the other a tumour cell | Blood cancers, some solid tumours |
| Cancer vaccines | Teach T cells a tumour's neoantigens, including personalised mRNA vaccines | Mostly in trials |
| Antibody drugs | Mark tumours for killing, or carry a poison directly to them | Breast cancer, lymphoma and others |
James Allison (for CTLA-4) and Tasuku Honjo (for PD-1) shared the 2018 Nobel Prize. Some patients with metastatic melanoma, which once meant death within about a year, now live for many years.
The price
Releasing the brakes has predictable costs, and they're autoimmune: colitis, thyroid problems, skin rashes, hepatitis and, rarely, diabetes or heart inflammation. These side effects reveal directly what those brakes normally hold back. CAR-T cells can release a dangerous flood of cytokines, a form of cytokine storm.
Not everyone responds. Often it's a minority, and predicting who will is hard. Immunotherapy doesn't work like the "boost your immune system" claims in supplement marketing: it removes specific brakes in a targeted way, using drugs with serious side effects.
The immune system can see cancer, and tumours survive by evolving ways to hide or to switch T cells off. Checkpoint drugs release those brakes, at the cost of some autoimmune side effects.